Early and mid-term outcomes of transcatheter closure of perimembranous ventricular septal defects using the Lifetech™ Konar-MF Occluder device (MFO)

Abstract

Background: Transcatheter closure of perimembranous ventricular septal defects is challenging. Double disk-designed devices have high adverse event rates; therefore, research into new devices persists. One such devise is the LifetechTM Konar-MF Occluder device (MFO), which is increasingly used. The purpose of this study is to present mid-term results of MFO for transcatheter closure of patients with perimembraneous ventricular septal defect. Patients and methods: Records of the 52 patients with perimembraneous ventricular septal defect who had undergone transcatheter closure with MFO were reviewed. Demographic, echocardiographic, and procedure details were investigated. Three years follow-up results were recorded. Results: We closed the perimembraneous ventricular septal defect in 51 of 52 patients (98%). The femoral venous approach was used in 27 patients (53 %) whilst no arteriovenous loop was established in the remaining patients. No significant procedure-related complication occurred. On day 1 echocardiography, the residual ventricular septal defect rate was 31%. Mean +/- SD (range) follow-up duration was 36 +/- 7,9 (18-54) months. At 6th month follow-up, only four patients had haemodynamically significant residual defects. No severe dysrhythmia was detected including complete heart block. A right bundle branch block pattern was seen in one patient. Conclusion: This study showed that MFO is a safe and effective device in the transcatheter treatment of perimembraneous ventricular septal defect's with mid-term follow-up.